Reactive nitrogen species, such as peroxynitrite, can nitrate tyrosine in proteins to form nitrotyrosine. Nitrotyrosine is metabolized to 3-nitro-4-hydroxyphenylacetic acid (NHPA), which is excreted in the urine. This has led to the notion that measurement of urinary NHPA may provide a time-integrated index of nitrotyrosine formation in vivo. However, it is not known whether NHPA is derived exclusively from metabolism of nitrotyrosine, or whether it can be formed by nitration of circulating parahydroxyphenylacetic acid (PHPA), a metabolite of tyrosine. In the present study, we have developed a gas chromatography MS assay for NHPA and PHPA to determine whether or not NHPA can be formed directly by nitration of PHPA. Following the injection of nitrotyrosine, 0.5 + − 0.16 % of injected dose was recovered unchanged as nitrotyrosine, and 4.3 + − 0. Since the plasma concentration of PHPA is markedly higher than free nitrotyrosine (approx. 400-fold), the nitration of high-circulating endogenous PHPA to form NHPA becomes very significant and accounts for the majority of NHPA excreted in urine. This is the first study to demonstrate that NHPA can be formed by nitration of PHPA in vivo, and that this is the major route for its formation.
INTRODUCTION
The pathological actions of reactive nitrogen species (RNS) are rooted in their ability to modify cell function through nitration, nitrosation or oxidation of cellular components, such as proteins, lipids or DNA [1] . In proteins, most nitration reactions occur on a tyrosine residue to form 3-nitrotyrosine [2, 3] , which is chemically stable. However, nitration of tyrosine can alter the protein's function, because nitration of tyrosine lowers the pK a of the phenolic group and thus affect the maintenance of protein conformation [4] [5] [6] . However, little is known about the fate of nitrated proteins in vivo. It has been postulated that there is increased proteolytic degradation of nitrated proteins [7] . For example, Souza et al. [7] have shown that nitration of tyrosine residue(s) in proteins is sufficient to induce an accelerated degradation of the modified proteins by the proteasome to release free amino acids as well as free nitrotyrosine. The urinary elimination of free nitrotyrosine is minimal, but its secondary metabolites can potentially serve as biomarkers of overall nitrotyrosine formation in vivo [8] . Since the pioneering work of Ohshima et al. [9] , it is known that nitrotyrosine is metabolized to 3-nitro-4-hydroxyphenylacetic acid (NHPA), which is excreted in the urine as the major urinary metabolite. This suggests that measurement of urinary NHPA could be used as a marker of systemic nitrotyrosine formation in vivo. It is not known, however, whether urinary NHPA is derived solely from metabolism Abbreviations used: GC, gas chromatography; LPS, lipopolysaccharide; NHPA, 3-nitro-4-hydroxyphenylacetic acid; [ 13 1 To whom correspondence should be addressed (e-mail kmoore@rfc.ucl.ac.uk).
of nitrotyrosine or whether it can also be formed by nitration of endogenous para-hydroxyphenylacetic acid (PHPA), a metabolite of tyrosine [10] and various phenolic compounds [11] . PHPA readily undergoes nitration in vitro [12] , and has been used as a chemical probe to monitor nitration reactions in vitro [13, 14] . However, it is not known whether or not this reaction occurs endogenously, and whether or not measurement of the formation of NHPA can be used as an index of nitration reactions in vivo.
The aims of the present study were thus to determine whether or not NHPA can be formed endogenously from nitration of circulating PHPA, and whether or not measurement of urinary NHPA can be used to monitor systemic nitration reactions in vivo.
EXPERIMENTAL

Chemicals
All chemicals were purchased from Sigma Aldrich (Poole, Dorset, U.K.) unless stated otherwise. ]tyrosine using Taiwan cobra (Naja naja atra) venom as a catalysing enzyme [15] . In brief, [ 13 C 9 ]tyrosine was added to 50 mM ammonium formate buffer (pH 7.4) at a concentration of 0.2 mg/ml, and venom was added at a concentration of 1 mg/ml, before incubation at 37
• C for approx. 2 h. • C for 8 h. The product was extracted with ethyl ethanoate and washed with water. After drying of the organic phase, the resulting materials were dissolved in 0.1 % (v/v) TFA/water (adjusted to pH 5.0 with ammonia solution) and were then applied to an LC 18 reverse-phase columns (Supelclean SPE tubes; Sigma) that had been pre-washed with 2 ml of methanol and 5 ml of 0.1 % (v/v) TFA/water (pH 5.0). The column was washed with 2 ml of water and [ 2 H 6 ]PHPA was eluted with 4 ml of 25 % (v/v) methanol in water.
The concentrations of 13 C-labelled and deuterated standards were determined against known amounts of unlabelled standards using the method described below. • C), dried under nitrogen and redissolved in 20 µl of n-undecane for analysis of NHPA or 50 µl of n-undecane for analysis of PHPA.
Measurement of plasma concentrations of NHPA and PHPA
To measure plasma levels of NHPA and PHPA, blood was taken from three male Sprague-Dawley rats into tubes containing EDTA, which were centrifuged at 2300 g for 30 min at 4
• C. The internal standards (10 ng of [ 13 C 8 ]NHPA or 100 ng of [ 13 C 8 ]PHPA) were added to 1 ml of plasma, which was immediately filtered by centrifugation at 9000 g in a microfuge through a 30 kDa molecular-mass cut-off centrifugal membrane (Ultrafree; Millipore, Bedford, MA, U.S.A.) to remove highmolecular-mass proteins. The filtrate was applied to an LC 18 reverse-phase column that had been pre-washed with 2 ml of methanol and 5 ml of 0.1 % (v/v) TFA/water (pH 5.0). The column was washed with 2 ml of water. Then NHPA and PHPA were eluted with 4 ml of 25 % (v/v) methanol in water and dried under vacuum before TLC extraction as described above. The samples were derivatized to the pentafluorobenzyl ester by the addition of 20 µl of 10 % (v/v) di-isopropyl ethylamine in acetonitrile and 40 µl of 10% (v/v) pentafluorobenzyl bromide in acetonitrile for 1 h at room temperature, dried under nitrogen and re-dissolved in 20 µl of n-undecane before GC (gas chromatography)/MS analysis.
GC/MS analysis of derivatized samples
Samples were analysed on a GC equipped with a 15 m DB-1701 (J&W Scientific, Folsom, CA, U.S.A.) capillary column (0.25 mm internal diameter, 0.25 µm film thickness) interfaced with a mass spectrometer (Trio 1000; Fisons Instruments, Beverly, MA, U.S.A.). The ion source and interface temperature were set at 200
• C and 300
• C respectively. Samples were analysed in negative-ion chemical ionization (NICI) mode with ammonia as the reagent gas, using 1 µl of each sample for injection. The initial column temperature was maintained at 150
• C for 1 min increasing to 300
• C at 20
• C/min. Samples were quantified by isotope-dilution GC/MS and ions were monitored at 376 and 384 mass units for NHPA and at 311 and 319 mass units for PHPA with single-ion monitoring. The concentrations were calculated from the known 13 C 8 -labelled internal standards, which are 8 mass units heavier than the authentic NHPA and PHPA.
Exclusion of artifactual nitration of PHPA during analysis
Initial studies using buffers at pH 4.0 showed that there was significant artifactual nitration of PHPA during the preparation of samples (results not shown). Therefore, to ensure that there was no artifactual nitration of PHPA during the preparation of urine samples, the formation of 
Standard curves for evaluation of the assays
To determine the accuracy of the assay, known amounts (0-20 ng of NHPA or 0-10 µg of PHPA) were added to 100 µl of human urine and the samples were analysed as unknowns. For measurement of intra-assay variability, six aliquots from a urine sample of one volunteer were analysed as described above and the intra-assay variability was calculated as percentage coefficients of variation (100 × S.D./mean).
Animal studies
Male Sprague Dawley rats (body mass 270-300 g) were obtained from the Comparative Biology Unit at the Royal Free and University College Medical School (Royal Free Campus, UCL, London, U.K.). All animal procedures were in accordance with Home Office recommendations. The animals were anaesthetized with an intraperitoneal injection of sodium pentobarbital (60 mg/ kg). The jugular vein and the urinary bladder were cannulated with polyethylene cannulae. Physiological saline solution was infused into the animals at 25 ml/kg per h through the jugular vein and urine samples were collected every 30 min as described below.
Metabolism of nitrotyrosine to NHPA
To determine the metabolism of nitrotyrosine to NHPA, 250 nmol of nitrotyrosine was dissolved in 1 ml of sterile PBS and was injected intravenously into three rats as a bolus. Urine samples were collected every 30 min for 5 h, with a single 30 min collection (basal) immediately before injection of nitrotyrosine. The urinary concentration of NHPA and PHPA was determined as described above. Urinary content of un-metabolized nitrotyrosine was also measured in each sample using GC with NICI MS, as previously described [17] . ]PHPA were then quantified by GC/MS using 13 C 8 -labelled internal standards. For measurement of the deuterium-labelled compounds, ion masses (m/z) of 381 and 337 were selected in selective-ion monitoring, which are 5 and 6 mass units heavier respectively than the authentic NHPA and PHPA.
Statistical analysis
All data are presented as means + − S.E.M. Statistical evaluation of the data was carried out with the analysis of variance (ANOVA) followed by the Newman-Keuls test for multiple comparisons, and P < 0.05 was considered statistically significant. 
RESULTS
To investigate the formation of NHPA in vivo, it was necessary to develop a method that can accurately measure this metabolite, and avoid the problems that are encountered during the assay of other nitrated products, such as nitrotyrosine [3, 17] . Thus the method needs to be reproducible with biological samples and free of artifactual nitration of its precursor (PHPA).
Characterization of the derivatives of NHPA and PHPA
The structures of the pentafluorobenzyl ester derivatives of NHPA and PHPA are shown in Figure 1 . The molecular mass of derivatized NHPA is 557 Da, which is 45 mass units heavier than derivatized PHPA (512 Da). The de-protonated molecular ion for the NHPA derivative is evident at m/z 556 [M-H] − and for PHPA at 511 [M-H] − , which are visible on the NICI spectra shown in Figure 1 . Analysis of the pentafluorobenzyl ester derivatives of NHPA and PHPA by full-scan mode (Figure 1) showed that NHPA has a dominant ion at m/z 376 ([M-181], loss of one pentafluorobenzyl ester group). PHPA has a dominant ion at m/z 331 [M-181], which is also compatible with the loss of a pentafluorobenzyl ester group. On the basis of these results, all further work was focused on developing the analytical method for NHPA and PHPA as the pentafluorobenzyl ester derivative with selective-ion monitoring at 376 and 331 mass units for NHPA and PHPA respectively. The detection limit was approx. 1 pg on column injection (for both NHPA and PHPA). After GC/MS analysis of urine samples, a single peak was eluted with the respective 13 C-labelled internal standards, which were 8 mass units heavier than the authentic NHPA and PHPA (Figure 2 ).
Standard curves of NHPA and PHPA
There was a good correlation between the added and measured amounts of NHPA (r 2 = 0.998) and PHPA (r 2 = 0.995) in urine, with a linear standard curve superimposed on the basal concentrations of these analytes (Figure 3 ). The intra-assay variation on a single urine sample was 7.4 % and 6.1 % for NHPA and PHPA respectively (n = 6).
Nitration of PHPA as an artifact
Artifactual nitration of PHPA during sample preparation was investigated after the addition of [ 2 H 6 ]PHPA to 100 µl of urine. Based on the evaluation of m/z 381 and retention time, no [ 2 H 5 ]NHPA was detected after extraction and derivatization of samples using the method described. However, if buffers of pH 4.0 or below were used, there was significant artifactual nitration (results not shown).
Effect of nitrotyrosine infusion on urinary NHPA and nitrotyrosine levels
The basal excretion rate of urinary NHPA in this group of rats was 8.1 + − 0.5 pmol/min (Figure 4) . Following the bolus injection of nitrotyrosine (250 nmol), the urinary excretion rate of NHPA increased to a peak of 84.8 + − 6.6 pmol/min within 30 min of injection. The urinary excretion of NHPA remained at 81.7 + − 12.2 pmol/min until 60 min, and thereafter decreased back towards baseline levels of 9.1 + − 1.5 pmol/min by 5 h (Figure 4) . These results indicate that only 4.3 + − 0.2 % of the injected nitrotyrosine is excreted as urinary NHPA. Free nitrotyrosine was undetectable in the urine under basal conditions. However, following the intravenous injection of 250 nmol of nitrotyrosine, urinary nitrotyrosine became detectable with an excretion rate of peaking at 16.8 + − 5.3 pmol/min at 30 min post-injection, and was undetectable by 4 h (Figure 4 ). Only 0.49 + − 0.16 % of the injected nitrotyrosine was excreted as urinary free nitrotyrosine.
Effect of LPS administration on urinary NHPA and nitrotyrosine levels
Injection of LPS into rats decreased the urine output from 26.5 + − 5.2 to 16.6 + − 7.1 µl/min. As shown in Figure 5 , there was initially no change in the urinary excretion of NHPA, but 2 h after the injection of LPS, there was a sustained increase in the urinary excretion of NHPA from 7.61 + − 1.3 to 15.7 + − 2.1 pmol/min (P < 0.01). Urinary nitrotyrosine was undetectable until 90 min after bolus injection of LPS, but, thereafter, small amounts of free nitrotyrosine were detectable (P < 0.01) ( Figure 5 ).
Nitration of infused [ 2 H 6 ]PHPA
In order to determine the extent of endogenous nitration of circulating PHPA in vivo, the formation of [ 2 H 5 ]NHPA was as infused PHPA, there is approx. 0.9 pmol/nmol of NHPA unaccounted for, and which is assumed to be derived from metabolism of nitrotyrosine. Injection of LPS resulted in a significant increase (P < 0.05) in the NHPA/PHPA ratio as well as the (Figure 8) . Meanwhile, the total recovery of [ 2 H 6 ]PHPA was significantly decreased after LPS administration (39.2 + − 4 % compared with 78 + − 2 %; P < 0.05) during 4 h of urine collection. We attribute this to the marked decrease in urine volume post-LPS.
Plasma concentrations of PHPA and NHPA
The plasma concentration of PHPA was 2.7 + − 1.1 µmol/l (410 + − 171 ng/ml) in rats. In contrast, the plasma concentrations of NHPA were undetectable.
DISCUSSION
One of the major disadvantages of measuring nitrotyrosine in tissues or biological fluids is that nitrated proteins are broken down at variable rates, and nitrotyrosine is metabolized and excreted [7, 9] . Thus the concept that measurement of NHPA, as the major urinary metabolite of nitrotyrosine, is attractive, since it can provide a time-integrated index of nitrotyrosine formation in vivo. However, it is important to know whether this metabolite is formed exclusively from nitrotyrosine, or whether it can be formed via nitration of PHPA, which is present at high concentrations in plasma.
Since the identification of NHPA as the major nitrotyrosine metabolite, there have been no reliable assays for the measurement of NHPA in biological fluids. For instance, an electrochemicalbased HPLC method has been described for the measurement of NHPA [18] , but the specificity and reproducibility of this method have not been evaluated so far. Beal et al. [19] have also reported an assay for measurement of NHPA in spinal tissue, but their method has the disadvantage that extractions are performed in extremely acidic conditions in which nitrite, always present in biological samples, can cause artifactual nitration of PHPA [12] . In the present study, we have described a novel assay for the Scheme 1 Two identified pathways, which can produce NHPA in vivo NHPA can be formed by either nitration of PHPA or catabolism of free nitrotyrosine. Tyrosine decarboxylase and tyramine oxidase are two identified metabolic enzymes that are responsible for conversion of tyrosine and nitrotyrosine into PHPA and NHPA. measurement of urinary NHPA, which has the advantage of being highly sensitive, specific and reproducible.
The major finding of this study is that urinary NHPA is not derived solely from nitrotyrosine metabolism and at least one other pathway is responsible for its formation in vivo (Scheme 1). The nitration of [ 2 H 6 ]PHPA to [ 2 H 5 ]NHPA provides unequivocal proof that nitration of circulating PHPA can occur. Indeed, based on our animal studies, we estimate that most of the urinary NHPA (approx. 85 %) is formed by nitration of PHPA in vivo in the rat, despite the fact that only a relatively small fraction of the infused PHPA is nitrated in vivo. This occurs because PHPA is present in plasma at a concentration of approx. 2.7 µmol/l, whereas free nitrotyrosine is only present at approx. 4.2 nmol/l [3] .
Although the major source of urinary NHPA is formed by nitration of endogenous PHPA, we also demonstrate that NHPA excretion increased after intravenous nitrotyrosine injection. Less than 5 % of injected nitrotyrosine was excreted in the urine as NHPA over 5 h, which is consistent with the observations of Tabrizi-Fard et al. [8] , who also observed that only 5-6 % of infused nitrotyrosine was metabolized to NHPA. The large volume of distribution of free nitrotyrosine [8] and the absence of detectable nitrotyrosine in normal urine suggest that there is cellular uptake as well as tubular re-absorption of free nitrotyrosine by various amino-acid transporters in the cell membrane. In contrast, 78 + − 2 % of injected [ 2 H 6 ]PHPA was rapidly excreted into the urine unchanged, demonstrating that there is little metabolism of this compound. Based on a plasma concentration of PHPA of 2.7 + − 1.1 µmol/l, and a urinary excretion rate of PHPA at 2.3 + − 0.7 nmol/min in rats, the renal clearance of PHPA is estimated to be approx. 0.85 ml/min. This value is very close to the glomerular filtration rate of our laboratory rats (1.02 + − 0.1 ml/min) [20] , and suggests that PHPA is simply filtered and not re-absorbed by the kidneys.
We have also shown that measurement of (Figure 8 ).
The present study has shown for the first time that endogenous PHPA can be nitrated to NHPA in vivo, which, until the present study, has been regarded as the major metabolite of nitrotyrosine. On a practical level, we have also shown that measurement of urinary NHPA can be used as a measure of nitration reactions in vivo. We conclude that the measurement of urinary NHPA excretion provides a time-integrated index of RNS formation in vivo, although it is not exclusively related to nitrotyrosine metabolism.
